PRISM Stock Indexes
Current Value
% Change (Daily)
% Change (Inception)
Top % Gainers
% Change
Top % Losers
% Change
Emerging Semiconductors $145.27 -3.83% 45.27% IPWR   6.73% ASYS   -12.20%
Emerging Pet Care $109.76 2.20% 9.76% WOOF   6.88% JAGX   -5.35%
Aerospace and Defense $141.15 0.07% 41.15% UAMY   10.19% VELO   -5.06%
AI Datacenter and Infrastructure $337.75 -1.45% 237.75% FLNC   2.72% BLZE   -12.08%
Beauty and Wellness $75.20 2.33% -24.80% HAIN   20.06% TRNR   -6.81%
Biotech $174.08 3.29% 74.08% PYXS   12.71% LSTA   -2.61%
Emerging Cannabis $109.24 3.95% 9.24% TSNDF   8.38% GRWG   -2.17%
Emerging Comms and Media $184.31 -0.18% 84.31% WBTN   3.52% APPS   -7.34%
Emerging Consumer Products $157.70 2.19% 57.70% WRBY   11.28% DIN   -3.35%
Emerging Crypto Mining $187.87 7.44% 87.87% BTCT   79.97% BTBT   -3.45%
Cybersecurity $142.25 -0.99% 42.25% AUID   5.08% CISO   -4.19%
Emerging EV $121.31 2.46% 21.31% GTEC   9.93% PSNY   -6.44%
Emerging Fintech $112.28 2.05% 12.28% BKKT   11.69% MRX   -2.35%
Emerging Global Health $187.78 3.16% 87.78% ABOS   14.96% GUTS   -4.34%
Emerging Healthcare $125.58 1.29% 25.58% HIMS   13.51% NVNO   -5.03%
Emerging NextGen Tech & AI $170.05 1.26% 70.05% QTEX   24.79% DUOT   -7.25%
Emerging New Energy $129.81 1.21% 29.81% SPWR   11.05% SKYQ   -8.96%
Emerging MedTech Index $145.21 1.40% 45.21% HUMA   26.34% INBS   -17.08%
Emerging Mental Health $166.08 2.22% 66.08% RVPH   8.70% NRXP   -3.20%
Emerging Oil & Gas $122.53 -0.59% 22.53% MXC   8.34% TPET   -19.54%
Emerging Pharmaceuticals $354.03 3.82% 254.03% RXRX   13.27% ATHA   -6.12%
Emerging Precious Metals $279.63 6.46% 179.63% DRD   14.53% NGD   -4.12%
Emerging Psychedelics $526.31 -1.21% 426.31% ATAI   0.96% PBM   -8.28%
Emerging Space $401.56 -1.25% 301.56% MOBX   8.72% VOYG   -8.03%
Emerging Sports $123.66 1.92% 23.66% SBET   12.56% STUB   -2.66%
Emerging Weight Loss $154.58 0.36% 54.58% VKTX   7.82% SKYE   -14.79%
Emerging Women’s Health $134.61 2.38% 34.61% FEMY   23.18% IVF   -20.98%
View All

PRISM View

UiPath Launches Maestro Flow to Help Developers Build and Govern AI Agent Workflows

Key Points Maestro Flow lets developers use coding agents such as Claude Code, Cursor, GitHub Copilot, and OpenAI Codex to create automation workflows from natural-language prompts. The product is designed to manage AI agents, robot...

Riot Platforms Sold 9,665 Bitcoin in H1 2026 to Fund a Data Center Pivot Anchored by a $9.1 Billion Anthropic Lease

Riot Platforms, Inc. (NASDAQ: RIOT), a vertically integrated digital infrastructure company spanning Bitcoin mining, engineering, and large-scale data center development, disclosed on August 18, 2026 that it sold 4,300 BTC in the second qua...

Aurora Cannabis Expands U.K. Medical Cannabis Distribution With £2.1 Million Deal

Key Points Aurora acquired 100% of Internode Pharma and HAP Pharma through a wholly owned subsidiary. The company paid £2.1 million in cash at closing, subject to certain post-closing conditions. Internode Pharma is a licensed U...

Palladyne AI and Orkid Tech Partner to Extend Pilot and SwarmOS Autonomy to Fixed-Wing UAVs

Palladyne AI Corp. (NASDAQ: PDYN), a U.S.-based defense and industrial technology company delivering embodied AI-powered collaborative autonomy solutions, announced a partnership with Orkid Tech on August 19, 2026 to integrate its Palladyne...

Trio-Tech Set to Join Nasdaq Global Market as AI and Auto Chip Demand Drives Growth

Key Points Trio-Tech’s Nasdaq Global Market listing is expected to begin at the market open on September 16, 2026. The company will retain its existing stock ticker, TRT. TRT will remain listed on NYSE American through the clo...

PRISM Mid-Day Movers: NextGen Tech & AI and Mental Health are Today’s leaders.

QTREX Quantum (QTEX) is up 30.92% today to 1.175 from Tuesday’s 0.8975 close. The shares opened at 0.9105, rose as high as 1.35, and have since pulled back, underscoring a volatile session; volume is 21.15 million shares, below the 30.36 ...

Better Home & Finance Sues Former CEO Vishal Garg Over Alleged Securities Law Violations

Key Points Better Home & Finance Holding Company filed a federal lawsuit against former CEO and founder Vishal Garg in the U.S. District Court for the Southern District of New York. Better alleges Garg coordinated with an undisc...

Blink Charging’s EnergyConnect Aims to Cut EV Charging Costs Without Grid Upgrades

Key Points EnergyConnect monitors energy use and dynamically allocates power among EV chargers at a site. Blink aims to reduce electricity costs, manage peak demand, and postpone expensive grid upgrades. The first deployment cove...

PRISM Mid-Day Movers: Pharmaceuticals and MedTech are Today’s Leaders.

Amylyx Pharmaceuticals (NASDAQ: AMLX) is rallying sharply today, up 49.42% to 32.02 from Monday’s 21.43 close after opening at 29.93. Shares have traded from 28.00 to a new 52-week high of 32.8099, while volume of 15.47 million shares is ...

Firefly Aerospace Gains Access to NASA Payload Processing Work at Vandenberg

Key Points Firefly is one of four companies selected through NASA’s contract on-ramp process. The contract has a combined ceiling value of $100 million and runs through February 1, 2033. Firefly can now bid on NASA task orders ...

Xos Stock Ignites as U.S. Air Force Contract Boosts Mobile Power Ambitions

Key Points Xos secured a contract with the U.S. Air Force to provide deployable mobile charging and energy-storage capabilities. The company will use its Xos Hub platform, which is designed to deliver portable, grid-independent powe...

Amylyx Surges 33% as Avexitide Hits Primary and All Secondary Endpoints in Phase 3 LUCIDITY Trial

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a clinical-stage pharmaceutical company, announced positive topline results on August 18, 2026 from the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (PBH). The trial met its...

Bio View

bioAffinity Opens a New Federal Sales Channel for CyPath Lung Through AvMEDICAL

Key Points AvMEDICAL will market CyPath Lung through its national sales team and established federal procurement network. The agreement targets VA medical centers and other U.S. government healthcare agencies. AvMEDICAL is a Serv...

CareCloud Wins AI Platform Project With KabaFusion for Home Infusion Operations

Key Points CareCloud will develop LailaCare, a customized AI-powered platform for KabaFusion’s home infusion and specialty pharmacy operations. The platform is intended to combine referral intake, insurance eligibility and author...

Alzamend Neuro’s AL001 Brain-Imaging Research Takes the Stage at ISMRM

Key Points AL001 data will be presented during a 10-minute oral session on September 29, 2026, at the ISMRM X-Nuclei MR Workshop. The completed Phase 1/2A study used 7-Tesla MRI and magnetic resonance spectroscopy to measure lithium...

InspireMD Targets Q4 FDA Decisions While Cutting $9 Million in Annual Costs

Key Points InspireMD expects potential FDA decisions in Q4 2026 for the CGuard Prime 80 cmsystem for transcarotid artery revascularization, or TCAR, and its original CGuard carotid artery stenting, or CAS, system. The company has...

Faeth Therapeutics Gains FDA Fast Track Status Ahead of Phase 2 Endometrial Cancer Readout

PIKTOR is designed to inhibit multiple points in a cancer-driving pathway, with topline data expected by year-end. Faeth Therapeutics (Nasdaq: FTH) has received FDA Fast Track designation for PIKTOR in combination with paclitaxel for a b...

Skye Bioscience’s Redx Deal Creates Fibrx Therapeutics With $125 Million in Funding

Key Points The companies expect the transaction to close in Q4 2026, subject to shareholder, regulatory, court, Nasdaq, and other approvals. Fibrx will be led by Redx’s executive team, with Lisa Anson expected to become CEO. ...

Ocular Therapeutix Rises After EyePoint’s Wet AMD Trial Miss Reshapes Competitive Landscape

Key Points EyePoint’s DURAVYU did not meet LUGANO’s primary endpoint of change from baseline in best-corrected visual acuity compared with aflibercept in the full patient dataset. EyePoint said nine of 211 participants, or about...

Femasys Bolsters Its Growth Plan With $30 Million Financing as FemBloc and FemaSeed Programs Advance

Key Points Femasys completed a $30 million private placement after June 30, with up to $60 million in potential additional proceeds if related warrants are exercised for cash. Q2 sales were $331,827, down 18.9% from a year earlier, ...

Allogene’s ALPHA3 Data and FDA Designations Sharpen the Case for Cema-Cel in Lymphoma

Key Points Allogene Therapeutics reported Q2 2026 results and a business update, highlighted by an interim futility analysis in the pivotal ALPHA3 trial of cema-cel in first-line large B-cell lymphoma (LBCL). Cema-cel achieved 58.3%...

MapLight Raises $150 Million as Schizophrenia Drug Development Broadens

Fresh capital follows positive Phase 2 data for ML-007C-MA as drug developers target cognition, negative symptoms and treatment adherence. Schizophrenia remains one of psychiatry’s most difficult diseases to treat. Antipsychotic drugs ...

Sagimet Clears FDA Hurdle to Move Denifanstat into Phase 3 for Acne

The planned 800-patient U.S. study will test an oral FASN inhibitor in moderate to severe acne, including approximately 450 adolescents. Sagimet Biosciences (Nasdaq: SGMT) is moving denifanstat toward late-stage development in the U.S. a...

Biomea Fusion Advances Icovamenib Into Obesity as First Patient Is Dosed in Semaglutide Combination Study

Key Points Biomea Fusion dosed the first participant in a new arm of the OPAL platform trial evaluating its oral small molecule icovamenib alongside low-dose semaglutide in overweight and obese adults. The randomized, double-blind s...

Q&A Corner

Building Regulated Infrastructure Across Traditional and Digital Asset Markets

This interview contains forward-looking statements, including statements regarding the proposed acquisitions, expected closing timelines, anticipated financial contributions and accretion, and planned regulatory filings. These statements ar...

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup